Encelion LLC v. Samsung Electronics: Wearable Health Sensing Patents Settled in 149 Days
Encelion LLC filed suit in the Eastern District of Texas alleging Samsung Electronics infringed two patents covering human hydration sensing and pulse sensor methods. The parties jointly moved to dismiss with prejudice after 149 days, suggesting a confidential resolution. Each party bore its own costs.
Wearable biosensor patents resolved swiftly in Texas infringement dispute
On November 16, 2024, Encelion LLC filed a patent infringement action against Samsung Electronics Co., Ltd. in the United States District Court for the Eastern District of Texas (Case No. 2:24-cv-00942). The complaint asserted two patents — US11980459B2, directed to a method and apparatus for human hydration sensing, and US11471072B2, covering a pulse sensor system and method — against Samsung’s wearable and health-monitoring product lines. Encelion was represented by Rabicoff Law LLC, a firm associated with NPE-style patent enforcement, while Samsung retained Gillam & Smith LLP.
The case closed on April 14, 2025, just 149 days after filing, via a joint motion to dismiss with prejudice. The court granted the motion, dismissing all claims and causes of action between the parties with prejudice — meaning Encelion cannot re-assert the same patents against Samsung on the same conduct in a future proceeding. The fee-neutral order, with each party bearing its own costs, is consistent with a confidential settlement in which financial terms were not disclosed to the public record.
A 149-day resolution in a multi-patent E.D. Texas action is notably fast, suggesting the parties reached agreement before significant litigation costs accumulated or claim construction proceedings began. Whether this reflects a licensing arrangement, a lump-sum payment, or a covenant not to sue is not ascertainable from the public record. The with-prejudice nature of the dismissal provides Samsung a degree of finality on the asserted claims, though it leaves the broader patent portfolio held by Encelion available for enforcement against other parties.
Filing to Dismissed with Prejudice in 149 days
149 days — notably swift for a multi-patent infringement action in E.D. Texas
Dismissed with prejudice: what the joint motion means for both parties
Dismissal with prejudice bars re-assertion of these claims
A dismissal with prejudice operates as a final adjudication on the merits, preventing the plaintiff from re-filing the same claims against the same defendant based on the same conduct. Here, Encelion agreed to this finality — typically in exchange for consideration — meaning neither US11980459B2 nor US11471072B2 can be re-asserted against Samsung for the accused acts.
Claim preclusion appliesEncelion trades future enforcement rights for likely settlement value
By agreeing to dismiss with prejudice, Encelion surrenders the ability to pursue Samsung further on these specific claims. This is consistent with a licensing payment or lump-sum settlement. The patents remain enforceable against other parties — only Samsung gains the benefit of finality. Encelion retains the broader portfolio for future assertion campaigns.
Settled — terms undisclosedSamsung secures finality on accused biosensor patent claims
Samsung obtains a with-prejudice dismissal, shielding it from Encelion re-litigating these two patents over the same accused products and conduct. The fee-neutral order suggests neither side extracted a cost award. Samsung avoided protracted E.D. Texas proceedings — a jurisdiction historically favorable to patent plaintiffs — likely concluding this was commercially preferable to continued litigation risk.
Samsung protected from re-suitWearable health sensing IP remains an active litigation vector
Hydration sensing and photoplethysmography-based pulse detection are core technologies in smartwatches and fitness wearables. Encelion’s patents cover methods applicable across the sector. Other OEMs shipping wearables with hydration or pulse sensing features remain potentially exposed to the same portfolio. The swift Samsung settlement may signal that Encelion is pursuing a broad licensing programme rather than a single-defendant strategy.
Broader portfolio risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Encelion LLC | Company | Patent assertion entity — holder of US11980459B2 and US11471072B2 in wearable biosensingSearch in Eureka ↗ |
| Defendant | Samsung Electronics Co., Ltd. | Company | Samsung Electronics Co., Ltd. — global consumer electronics and wearable health device manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Isaac Phillip Rabicoff | Attorney | Counsel for Encelion LLCSearch in Eureka ↗ |
| Plaintiff law firm | Rabicoff Law LLC | Law Firm | Representing Encelion LLCSearch in Eureka ↗ |
| Defendant counsel | Melissa Richards Smith | Attorney | Counsel for Samsung Electronics Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Gillam & Smith LLP | Law Firm | Representing Samsung Electronics Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Texas Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order granting the joint motion confirms a consensual resolution — not a merits adjudication. The with-prejudice designation is legally significant: it functions as a final judgment, barring Encelion from re-asserting US11980459B2 and US11471072B2 against Samsung on the same accused conduct. The fee-neutral provision — each party bearing its own costs — is the standard outcome in patent settlements and does not indicate fault or litigation weakness on either side. The public record is silent on financial terms.
US11980459B2 & US11471072B2 — Human Hydration Sensing and Pulse Sensor Technology
US11980459B2 (application US17/936284) covers a method and apparatus for human hydration sensing — technology that measures physiological hydration status, likely through bioelectrical impedance or optical sensing integrated into wearable form factors. US11471072B2 (application US17/206065) protects a pulse sensor system and method, encompassing signal acquisition, processing, and output relevant to heart rate and cardiovascular monitoring. Both patents sit at the intersection of biosensor hardware and signal processing algorithms, a technically dense domain with direct commercial application in smartwatches, fitness bands, and clinical wearables.
These patents are strategically positioned to capture broad commercial value in the wearable health technology sector. Hydration sensing and pulse monitoring are now standard features in consumer wearables shipped by Samsung, Apple, Garmin, Fitbit, and others. Method claims in this space are particularly potent because they attach to the act of performing the sensing function — making design-around difficult without fundamentally changing the measurement approach. Any OEM incorporating optical or bioelectrical sensing into a wearable product should treat these patents as material to a freedom-to-operate assessment.
Should your wearable product team run an FTO against US11980459B2 and US11471072B2?
If your organisation develops or manufactures wearables incorporating hydration sensing, photoplethysmography (PPG), or bioelectrical impedance analysis (BIA), both Encelion patents warrant a formal freedom-to-operate review. The Samsung settlement confirms Encelion is actively enforcing this portfolio. Method claims in hydration and pulse sensing are difficult to avoid through hardware-only design changes, making early-stage FTO analysis essential for product roadmap decisions and M&A due diligence.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US11980459B2 and US11471072B2 against your product specifications, identify prior art that may limit claim breadth, and surface continuation applications that could expand enforcement risk. Eureka’s patent family analysis tools allow R&D and IP teams to monitor new filings from the same application lineage — giving early warning before new claims are asserted against next-generation wearable designs.
Run a freedom-to-operate analysis on US11980459B2 to assess your product’s exposure
Run FTO in Eureka →Similar wearable biosensor patent cases filed in E.D. Texas
Cases involving wearable health sensing and biosensor method patents litigated in the Eastern District of Texas, with comparable NPE assertion patterns.
What this case signals for the wearable health sensing IP landscape
A fast-resolved E.D. Texas action against Samsung over biosensor patents warrants monitoring by every wearable OEM and health tech platform.
E.D. Texas remains a preferred venue for biosensor patent assertions
Encelion’s choice of the Eastern District of Texas is strategically deliberate. The court’s plaintiff-friendly reputation, efficient case management, and jury pool make it a high-pressure venue for defendants. Samsung’s rapid settlement suggests the commercial calculus favoured resolution over contesting jurisdiction or merits in this forum.
With-prejudice dismissal is the gold standard for defendant finality
Samsung’s insistence on — or acceptance of — a with-prejudice dismissal is the correct risk-management posture. It prevents Encelion from retooling the same infringement theory and re-filing. Companies facing NPE assertions should always negotiate for with-prejudice terms, as without-prejudice dismissals leave the door open to re-litigation.
Encelion v Samsung — key questions answered
Encelion asserted two patents: US11980459B2, covering a method and apparatus for human hydration sensing, and US11471072B2, covering a pulse sensor system and method. Both patents relate to wearable biosensing technology applicable to smartwatches and fitness wearables.
The parties filed a joint motion representing the case had been resolved, consistent with a confidential settlement. Dismissal with prejudice means Encelion cannot re-assert the same patents against Samsung for the same accused conduct. It operates as a final judgment on the merits and provides Samsung with claim preclusion protection.
The case lasted 149 days from filing to closure — notably fast for a multi-patent infringement action in the Eastern District of Texas, where cases routinely take 18–36 months to trial. The rapid resolution suggests early settlement negotiations, likely before significant discovery or claim construction proceedings commenced.
The court ordered each party to bear its own costs, expenses, and attorneys’ fees. This is standard in patent settlements and does not reflect a finding of fault, frivolity, or exceptionality. It contrasts with cases where a court awards fees under 35 U.S.C. § 285 — no such finding was made here.
Yes. The with-prejudice dismissal protects only Samsung from re-assertion on the accused conduct. The patents remain fully enforceable against other parties. Wearable manufacturers incorporating hydration sensing or optical pulse detection features should consider a freedom-to-operate review against both patents, particularly given Encelion’s demonstrated willingness to litigate in E.D. Texas.
PatSnap Eureka searches patents and litigation data to answer instantly.